Filling Vials for Pandemic Preparedness
| Director: Gregory Korbutt | ACTM Director: Gayle Piat |
| BRIF: 5.7M |
¾ÅÐãÖ±²¥ Cell Therapy Manufacturing (ACTM) is a contract development and manufacturing organization located in the Li Ka Shing Centre for Health Research Innovation at the ¾ÅÐãÖ±²¥. This state-of-the-art GMP cleanroom facility supports the manufacturing and preparation of clinical therapies, including cell-based therapies and vaccines. It is the only one of its kind in Western Canada, and one of few such facilities in Canada. It is led by Dr. Gregory Korbutt and the director of the ACTM is Gayle Piat. This program builds on existing infrastructure to aid in maintaining and monitoring the aseptic environment, facilitate quality control testing, accommodate product storage, and increase the flexibility of filling container sizes and types.
Their BRIF Infrastructure funding will:
- Support "Fill and Finish" -- the final steps in vaccine production. ACTM is in the process of installing a robotic aseptic fill/finish system, which will increase its capacity to produce therapies significantly.
- Provide the final components required to meet stringent regulatory requirements and offer greater flexibility to support a broad range of pandemic-relevant projects in Canada.
- Newly awarded funding will support process monitoring, quality control, product storage, and flexibility in outputs such as container sizes and types.
Team Members
Gregory Korbutt, ¾ÅÐãÖ±²¥
Marisa Akow, Ottawa Hospital Research Institute
John Bell, University of Ottawa
Trina Racine, VIDO
Gayle Piat, ¾ÅÐãÖ±²¥
Jennifer Quizi, Ottawa Hospital Research Institute
Brian Lichty, McMaster University